Close the left navigation
  1. Grignaschi S, Kim M, Zanframundo G, Ravichandran N, Lilleker JB, Sen P, Joshi M, Agarwal V, Kardes S, Day J, Makol A, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, Nikiphorou E, Chatterjee T, Tan AL, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Nune A, Distler O, Chinoy H, Cavagna L, Agarwal V, Aggarwal R, Gupta L; COVAD study group. High fatigue scores in patients with idiopathic inflammatory myopathies: a multigroup comparative study from the COVAD e-survey. Rheumatol Int. 2023 Sep;43(9):1637-1649. doi: 10.1007/s00296-023-05344-z. Epub 2023 Jun 14. [Abstract Grignaschi S, Kim M, Zanframundo G, Ravichandran N, Lilleker JB, Sen P, Joshi M, Agarwal V, Kardes S, Day J, Makol A, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, Nikiphorou E, Chatterjee T, Tan AL, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Nune A, Distler O, Chinoy H, Cavagna L, Agarwal V, Aggarwal R, Gupta L; COVAD study group. High fatigue scores in patients with idiopathic inflammatory myopathies: a multigroup comparative study from the COVAD e-survey. Rheumatol Int. 2023 Sep;43(9):1637-1649. doi: 10.1007/s00296-023-05344-z. Epub 2023 Jun 14.]
  2. Duvvuri B, Pachman LM, Hermanson P, Wang T, Moore R, Ding-Hwa Wang D, Long A, Morgan GA, Doty S, Tian R, Sancak Y, Lood C. Role of mitochondria in the myopathy of juvenile dermatomyositis and implications for skeletal muscle calcinosis. J Autoimmun. 2023 Jul;138:103061. doi: 10.1016/j.jaut.2023.103061. [Abstract Duvvuri B, Pachman LM, Hermanson P, Wang T, Moore R, Ding-Hwa Wang D, Long A, Morgan GA, Doty S, Tian R, Sancak Y, Lood C. Role of mitochondria in the myopathy of juvenile dermatomyositis and implications for skeletal muscle calcinosis. J Autoimmun. 2023 Jul;138:103061. doi: 10.1016/j.jaut.2023.103061.]
  3. Symonds T, Randall J, Lloyd-Price L, Hudgens S, Dimachkie MM, Guldberg C, Machado PM. Study to Assess Content Validity and Interrater and Intrarater Reliability of the Inclusion Body Myositis Functional Rating Scale. Neurol Clin Pract. 2023 Aug;13(4):e200168. doi: 10.1212/CPJ.0000000000200168. Epub 2023 Jun 12. [Abstract Symonds T, Randall J, Lloyd-Price L, Hudgens S, Dimachkie MM, Guldberg C, Machado PM. Study to Assess Content Validity and Interrater and Intrarater Reliability of the Inclusion Body Myositis Functional Rating Scale. Neurol Clin Pract. 2023 Aug;13(4):e200168. doi: 10.1212/CPJ.0000000000200168. Epub 2023 Jun 12.]
  4. Keret S, Saygin D, Moghadam-Kia S, Ren D, Oddis CV, Aggarwal R. Discordance between patient and physician-reported disease activity in adult idiopathic inflammatory myopathy. Rheumatology (Oxford). 2023 Jun 22:kead316. doi: 10.1093/rheumatology/kead316. Epub ahead of print. [Abstract Keret S, Saygin D, Moghadam-Kia S, Ren D, Oddis CV, Aggarwal R. Discordance between patient and physician-reported disease activity in adult idiopathic inflammatory myopathy. Rheumatology (Oxford). 2023 Jun 22:kead316. doi: 10.1093/rheumatology/kead316. Epub ahead of print.]
  5. Zubair AS, Salam S, Dimachkie MM, Machado PM, Roy B. Imaging biomarkers in the idiopathic inflammatory myopathies. Front Neurol. 2023 Apr 25;14:1146015. doi: 10.3389/fneur.2023.1146015. [Abstract Zubair AS, Salam S, Dimachkie MM, Machado PM, Roy B. Imaging biomarkers in the idiopathic inflammatory myopathies. Front Neurol. 2023 Apr 25;14:1146015. doi: 10.3389/fneur.2023.1146015.]
  6. De Paepe B. Incorporating circulating cytokines into the idiopathic inflammatory myopathy subclassification toolkit. Front Med (Lausanne). 2023 Mar 16;10:1130614. doi: 10.3389/fmed.2023.1130614. [Abstract De Paepe B. Incorporating circulating cytokines into the idiopathic inflammatory myopathy subclassification toolkit. Front Med (Lausanne). 2023 Mar 16;10:1130614. doi: 10.3389/fmed.2023.1130614.]
  7. DiRenzo D, Saygin D, de Groot I, Bingham Iii CO, Lundberg IE, Needham M, Park JK, Regardt M, Sarver C, Song YW, Maxwell L, Beaton D, de Visser M, Christopher-Stine L, Mecoli CA, Alexanderson H. Reliability and validity of PROMIS physical function, pain interference, and fatigue as patient reported outcome measures in adult idiopathic inflammatory myopathies: International study from the OMERACT myositis working group. Semin Arthritis Rheum. 2023 Feb;58:152111. doi: 10.1016/j.semarthrit.2022.152111. Epub 2022 Nov 3. [Abstract DiRenzo D, Saygin D, de Groot I, Bingham Iii CO, Lundberg IE, Needham M, Park JK, Regardt M, Sarver C, Song YW, Maxwell L, Beaton D, de Visser M, Christopher-Stine L, Mecoli CA, Alexanderson H. Reliability and validity of PROMIS physical function, pain interference, and fatigue as patient reported outcome measures in adult idiopathic inflammatory myopathies: International study from the OMERACT myositis working group. Semin Arthritis Rheum. 2023 Feb;58:152111. doi: 10.1016/j.semarthrit.2022.152111. Epub 2022 Nov 3.]
  8. Patel RN, Esparza VG, Lai JS, Gray EL, Reeve BB, Chang RW, Cella D, Ardalan K. Comparison of Patient-Reported Outcomes Measurement Information System Computerized Adaptive Testing Versus Fixed Short Forms in Juvenile Myositis. Arthritis Care Res (Hoboken). 2023 Feb;75(2):381-390. doi: 10.1002/acr.24760. Epub 2022 Aug 31. [Abstract Patel RN, Esparza VG, Lai JS, Gray EL, Reeve BB, Chang RW, Cella D, Ardalan K. Comparison of Patient-Reported Outcomes Measurement Information System Computerized Adaptive Testing Versus Fixed Short Forms in Juvenile Myositis. Arthritis Care Res (Hoboken). 2023 Feb;75(2):381-390. doi: 10.1002/acr.24760. Epub 2022 Aug 31.]
  9. Oldroyd AGS, Krogh NS, Dixon WG, Chinoy H. Investigating characteristics of idiopathic inflammatory myopathy flares using daily symptom data collected via a smartphone app. Rheumatology (Oxford). 2022 Nov 28;61(12):4845-4854. doi: 10.1093/rheumatology/keac161. [Abstract Oldroyd AGS, Krogh NS, Dixon WG, Chinoy H. Investigating characteristics of idiopathic inflammatory myopathy flares using daily symptom data collected via a smartphone app. Rheumatology (Oxford). 2022 Nov 28;61(12):4845-4854. doi: 10.1093/rheumatology/keac161.]
  10. Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Csörgő Z, Dimachkie MM, Griger Z, Moiseev S, Oddis C, Schiopu E, Vencovský J, Beckmann I, Clodi E, Bugrova O, Dankó K, Ernste F, Goyal NA, Heuer M, Hudson M, Hussain YM, Karam C, Magnolo N, Nelson R, Pozur N, Prystupa L, Sárdy M, Valenzuela G, van der Kooi AJ, Vu T, Worm M, Levine T; ProDERM Trial Group. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med. 2022 Oct 6;387(14):1264-1278. doi: 10.1056/NEJMoa2117912. [Abstract Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Csörgő Z, Dimachkie MM, Griger Z, Moiseev S, Oddis C, Schiopu E, Vencovský J, Beckmann I, Clodi E, Bugrova O, Dankó K, Ernste F, Goyal NA, Heuer M, Hudson M, Hussain YM, Karam C, Magnolo N, Nelson R, Pozur N, Prystupa L, Sárdy M, Valenzuela G, van der Kooi AJ, Vu T, Worm M, Levine T; ProDERM Trial Group. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med. 2022 Oct 6;387(14):1264-1278. doi: 10.1056/NEJMoa2117912.]
  11. Oddis CV, Rockette HE, Zhu L, Koontz DC, Lacomis D, Venturupalli S, Moghadam-Kia S, Ascherman DP, Crofford L, Dimachkie MM, Ernste F, Gazeley D, Marder G, Aggarwal R. Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis. ACR Open Rheumatol. 2022 Nov;4(11):983-990. doi: 10.1002/acr2.11493. Epub 2022 Sep 20. [Abstract Oddis CV, Rockette HE, Zhu L, Koontz DC, Lacomis D, Venturupalli S, Moghadam-Kia S, Ascherman DP, Crofford L, Dimachkie MM, Ernste F, Gazeley D, Marder G, Aggarwal R. Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis. ACR Open Rheumatol. 2022 Nov;4(11):983-990. doi: 10.1002/acr2.11493. Epub 2022 Sep 20.]
  12. Saygin D, Rockette-Wagner B, Oddis C, Neiman N, Koontz D, Moghadam-Kia S, Aggarwal R. Consumer-based activity trackers in evaluation of physical activity in myositis patients. Rheumatology (Oxford). 2022 Jul 6;61(7):2951-2958. doi: 10.1093/rheumatology/keab700. [Abstract Saygin D, Rockette-Wagner B, Oddis C, Neiman N, Koontz D, Moghadam-Kia S, Aggarwal R. Consumer-based activity trackers in evaluation of physical activity in myositis patients. Rheumatology (Oxford). 2022 Jul 6;61(7):2951-2958. doi: 10.1093/rheumatology/keab700.]
  13. Davuluri S, Duvvuri B, Lood C, Faghihi-Kashani S, Chung L. Calcinosis in dermatomyositis: Origins and possible therapeutic avenues. Best Pract Res Clin Rheumatol. 2022 Jun;36(2):101768. doi: 10.1016/j.berh.2022.101768. [Abstract Davuluri S, Duvvuri B, Lood C, Faghihi-Kashani S, Chung L. Calcinosis in dermatomyositis: Origins and possible therapeutic avenues. Best Pract Res Clin Rheumatol. 2022 Jun;36(2):101768. doi: 10.1016/j.berh.2022.101768.]
  14. Naveen R, Thakare DR, Agarwal V, Aggarwal R, Gupta L. Validation of two simple patient-centered outcome measures for virtual monitoring of patients with idiopathic inflammatory myositis. Clin Rheumatol. 2022 Mar;41(3):765-772. doi: 10.1007/s10067-021-05990-3. Epub 2021 Nov 17. [Abstract Naveen R, Thakare DR, Agarwal V, Aggarwal R, Gupta L. Validation of two simple patient-centered outcome measures for virtual monitoring of patients with idiopathic inflammatory myositis. Clin Rheumatol. 2022 Mar;41(3):765-772. doi: 10.1007/s10067-021-05990-3. Epub 2021 Nov 17.]
  15. Oldroyd AGS, Lilleker JB, Amin T, Aragon O, Bechman K, Cuthbert V, Galloway J, Gordon P, Gregory WJ, Gunawardena H, Hanna MG, Isenberg D, Jackman J, Kiely PDW, Livermore P, Machado PM, Maillard S, McHugh N, Murphy R, Pilkington C, Prabu A, Rushe P, Spinty S, Swan J, Tahir H, Tansley SL, Truepenny P, Truepenny Y, Warrier K, Yates M, Papadopoulou C, Martin N, McCann L, Chinoy H. British Society for Rheumatology Standards, Audit and Guidelines Working Group. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology (Oxford). 2022 Mar 31:keac115. doi: 10.1093/rheumatology/keac115. Online ahead of print. [Abstract Oldroyd AGS, Lilleker JB, Amin T, Aragon O, Bechman K, Cuthbert V, Galloway J, Gordon P, Gregory WJ, Gunawardena H, Hanna MG, Isenberg D, Jackman J, Kiely PDW, Livermore P, Machado PM, Maillard S, McHugh N, Murphy R, Pilkington C, Prabu A, Rushe P, Spinty S, Swan J, Tahir H, Tansley SL, Truepenny P, Truepenny Y, Warrier K, Yates M, Papadopoulou C, Martin N, McCann L, Chinoy H. British Society for Rheumatology Standards, Audit and Guidelines Working Group. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology (Oxford). 2022 Mar 31:keac115. doi: 10.1093/rheumatology/keac115. Online ahead of print.]
  16. Schmidt J, Korsten P, Zechel S, Schlüter S. Introducing the international Myositis Society (iMyoS): a novel multiprofessional society to foster the care, education, and research on myositis. Clin Exp Rheumatol. 2022 Feb;40(2):210-213. [Abstract Schmidt J, Korsten P, Zechel S, Schlüter S. Introducing the international Myositis Society (iMyoS): a novel multiprofessional society to foster the care, education, and research on myositis. Clin Exp Rheumatol. 2022 Feb;40(2):210-213.]
  17. Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, Mammen AL, Miller FW. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021 Dec 2;7(1):86. doi: 10.1038/s41572-021-00321-x. [Abstract Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, Mammen AL, Miller FW. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021 Dec 2;7(1):86. doi: 10.1038/s41572-021-00321-x.]
  18. Saygin D, Oddis CV, Dzanko S, Koontz D, Moghadam-Kia S, Ardalan K, Coles TM, Aggarwal R. Utility of patient-reported outcomes measurement information system (PROMIS) physical function form in inflammatory myopathy. Semin Arthritis Rheum. 2021 Jun;51(3):539-546. doi: 10.1016/j.semarthrit.2021.03.018. Epub 2021 Apr 15. [Abstract Saygin D, Oddis CV, Dzanko S, Koontz D, Moghadam-Kia S, Ardalan K, Coles TM, Aggarwal R. Utility of patient-reported outcomes measurement information system (PROMIS) physical function form in inflammatory myopathy. Semin Arthritis Rheum. 2021 Jun;51(3):539-546. doi: 10.1016/j.semarthrit.2021.03.018. Epub 2021 Apr 15.]
  19. Rosina S, Varnier GC, Pistorio A, Pilkington C, Maillard S, Civino A, Tsitsami E, Bracaglia C, Jelusic M, Cespedes-Cruz A, Espada G, Cimaz R, Couillault G, Joos R, Quartier P, Rao AP, Malattia C, Ruperto N, Consolaro A, Ravelli A; Pediatric Rheumatology International Trials Organization (PRINTO). Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile Dermatomyositis. J Rheumatol. 2021 Jun;48(6):898-906. doi: 10.3899/jrheum.200543. [Abstract Rosina S, Varnier GC, Pistorio A, Pilkington C, Maillard S, Civino A, Tsitsami E, Bracaglia C, Jelusic M, Cespedes-Cruz A, Espada G, Cimaz R, Couillault G, Joos R, Quartier P, Rao AP, Malattia C, Ruperto N, Consolaro A, Ravelli A; Pediatric Rheumatology International Trials Organization (PRINTO). Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile Dermatomyositis. J Rheumatol. 2021 Jun;48(6):898-906. doi: 10.3899/jrheum.200543.]
  20. Aggarwal R, Charles-Schoeman C, Schessl J, Dimachkie MM, Beckmann I, Levine T. Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis ("ProDERM Study"). Medicine (Baltimore). 2021 Jan 8;100(1):e23677. doi: 10.1097/MD.0000000000023677. [Abstract Aggarwal R, Charles-Schoeman C, Schessl J, Dimachkie MM, Beckmann I, Levine T. Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis ("ProDERM Study"). Medicine (Baltimore). 2021 Jan 8;100(1):e23677. doi: 10.1097/MD.0000000000023677.]
  21. Rosina S, Consolaro A, van Dijkhuizen P, Pistorio A, Varnier GC, Bovis F, Nistala K, Maillard S, Civino A, Tsitsami E, de Inocencio J, Jelusic M, Vojinovic J, Espada G, Makay B, Katsicas MM, Pratsidou-Gertsi P, Lazarevic D, Rao AP, Pires Marafon D, Martini A, Pilkington C, Ruperto N, Ravelli A. Development and Validation of a Composite Disease Activity Score for Measurement of Muscle and Skin Involvement in Juvenile Dermatomyositis. Rheumatology (Oxford). 2019;58(7):1196–1205. doi:10.1093/rheumatology/key421. [Abstract Rosina S, Consolaro A, van Dijkhuizen P, Pistorio A, Varnier GC, Bovis F, Nistala K, Maillard S, Civino A, Tsitsami E, de Inocencio J, Jelusic M, Vojinovic J, Espada G, Makay B, Katsicas MM, Pratsidou-Gertsi P, Lazarevic D, Rao AP, Pires Marafon D, Martini A, Pilkington C, Ruperto N, Ravelli A. Development and Validation of a Composite Disease Activity Score for Measurement of Muscle and Skin Involvement in Juvenile Dermatomyositis. Rheumatology (Oxford). 2019;58(7):1196–1205. doi:10.1093/rheumatology/key421.]
  22. Concha JSS, Tarazi M, Kushner CJ, Gaffney RG, Werth VP. The Diagnosis and Classification of Amyopathic Dermatomyositis: A Historical Review and Assessment of Existing Criteria. Br J Dermatol. 2019;180(5):1001–1008. doi:10.1111/bjd.17536. [Abstract Concha JSS, Tarazi M, Kushner CJ, Gaffney RG, Werth VP. The Diagnosis and Classification of Amyopathic Dermatomyositis: A Historical Review and Assessment of Existing Criteria. Br J Dermatol. 2019;180(5):1001–1008. doi:10.1111/bjd.17536.]
  23. Tjärnlund A, Tang Q, Wick C, Dastmalchi M, Mann H, Tomasová Studýnková J, Chura R, Gullick NJ, Salerno R, Rönnelid J, Alexanderson H, Lindroos E, Aggarwal R, Gordon P, Vencovsky J, Lundberg IE. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis. 2018 Jan;77(1):55-62. doi: 10.1136/annrheumdis-2017-211751. [Abstract Tjärnlund A, Tang Q, Wick C, Dastmalchi M, Mann H, Tomasová Studýnková J, Chura R, Gullick NJ, Salerno R, Rönnelid J, Alexanderson H, Lindroos E, Aggarwal R, Gordon P, Vencovsky J, Lundberg IE. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis. 2018 Jan;77(1):55-62. doi: 10.1136/annrheumdis-2017-211751.]
  24. Naddaf E, Barohn RJ, Dimachkie MM. Inclusion Body Myositis: Update on Pathogenesis and Treatment. Neurotherapeutics. 2018 Oct;15(4):995-1005. doi: 10.1007/s13311-018-0658-8. PMID: 30136253; PMCID: PMC6277289. [Abstract Naddaf E, Barohn RJ, Dimachkie MM. Inclusion Body Myositis: Update on Pathogenesis and Treatment. Neurotherapeutics. 2018 Oct;15(4):995-1005. doi: 10.1007/s13311-018-0658-8. PMID: 30136253; PMCID: PMC6277289.]
  25. Varnier GC, Rosina S, Ferrari C, Pistorio A, Consolaro A, Bovis F, Dalprà S, Pilkington C, Maillard S, Civino A, Tsitsami E, de Inocencio J, Jelusic M, Vojinovic J, Espada G, Makay B, Katsicas MM, Pratsidou-Gertsi P, Lazarevic D, Rao AP, Marafon DP, Ruperto N, Martini A, Ravelli A. Development and Testing of a Hybrid Measure of Muscle Strength in Juvenile Dermatomyositis for Use in Routine Care. Arthritis Care Res (Hoboken). 2018;70(9):1312–1319. doi:10.1002/acr.23491. [Abstract Varnier GC, Rosina S, Ferrari C, Pistorio A, Consolaro A, Bovis F, Dalprà S, Pilkington C, Maillard S, Civino A, Tsitsami E, de Inocencio J, Jelusic M, Vojinovic J, Espada G, Makay B, Katsicas MM, Pratsidou-Gertsi P, Lazarevic D, Rao AP, Marafon DP, Ruperto N, Martini A, Ravelli A. Development and Testing of a Hybrid Measure of Muscle Strength in Juvenile Dermatomyositis for Use in Routine Care. Arthritis Care Res (Hoboken). 2018;70(9):1312–1319. doi:10.1002/acr.23491.]
  26. Alexanderson H. Exercise in Myositis. Curr Treatm Opt Rheumatol. 2018;4(4):289–298. doi:10.1007/s40674-018-0113-3. [Abstract Alexanderson H. Exercise in Myositis. Curr Treatm Opt Rheumatol. 2018;4(4):289–298. doi:10.1007/s40674-018-0113-3.]
  27. McHugh NJ, Tansley SL. Autoantibodies in Myositis. Nat Rev Rheumatol. 2018;14(5):290–302. doi:10.1038/nrrheum.2018.56. [Abstract McHugh NJ, Tansley SL. Autoantibodies in Myositis. Nat Rev Rheumatol. 2018;14(5):290–302. doi:10.1038/nrrheum.2018.56.]
  28. Chansky PB, Olazagasti JM, Feng R, Werth VP. Cutaneous Dermatomyositis Disease Course Followed Over Time Using the Cutaneous Dermatomyositis Disease Area and Severity Index. J Am Acad Dermatol. 2018;79(3):464–469.e2. doi:10.1016/j.jaad.2017.10.022. [Abstract Chansky PB, Olazagasti JM, Feng R, Werth VP. Cutaneous Dermatomyositis Disease Course Followed Over Time Using the Cutaneous Dermatomyositis Disease Area and Severity Index. J Am Acad Dermatol. 2018;79(3):464–469.e2. doi:10.1016/j.jaad.2017.10.022.]
  29. Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, Lahdenne P, Magnusson B, Nistala K, Ozen S, Pilkington C, Ravelli A, Russo R, Uziel Y, van Brussel M, van der Net J, Vastert S, Wedderburn LR, Wulffraat N, McCann LJ, van Royen-Kerkhof A. Consensus-based Recommendations for the Management of Juvenile Dermatomyositis. Ann Rheum Dis. 2017;76(2):329–340. doi:10.1136/annrheumdis-2016-209247. [Abstract Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, Lahdenne P, Magnusson B, Nistala K, Ozen S, Pilkington C, Ravelli A, Russo R, Uziel Y, van Brussel M, van der Net J, Vastert S, Wedderburn LR, Wulffraat N, McCann LJ, van Royen-Kerkhof A. Consensus-based Recommendations for the Management of Juvenile Dermatomyositis. Ann Rheum Dis. 2017;76(2):329–340. doi:10.1136/annrheumdis-2016-209247.]
  30. Tiao J, Feng R, Berger EM, Brandsema JF, Coughlin CC, Khan N, Kichula EA, Lerman MA, Lvovich S, McMahon PJ, Rider LG, Rubin AI, Scalzi LV, Smith DM, Taxter AJ, Treat JR, Williams RP, Yum SW, Okawa J, Werth VP. Evaluation of the Reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-binary Method in Juvenile Dermatomyositis Among Paediatric Dermatologists, Rheumatologists and Neurologists. Br J Dermatol. 2017;177(4):1086–1092. doi:10.1111/bjd.15596. [Abstract Tiao J, Feng R, Berger EM, Brandsema JF, Coughlin CC, Khan N, Kichula EA, Lerman MA, Lvovich S, McMahon PJ, Rider LG, Rubin AI, Scalzi LV, Smith DM, Taxter AJ, Treat JR, Williams RP, Yum SW, Okawa J, Werth VP. Evaluation of the Reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-binary Method in Juvenile Dermatomyositis Among Paediatric Dermatologists, Rheumatologists and Neurologists. Br J Dermatol. 2017;177(4):1086–1092. doi:10.1111/bjd.15596.]
  31. Varnier GC, Rosina S, Ferrari C, Pistorio A, Consolaro A, Bovis F, Dalprà S, Pilkington C, Maillard S, Civino A, Tsitsami E, de Inocencio J, Jelusic M, Vojinovic J, Espada G, Makay B, Katsicas MM, Pratsidou-Gertsi P, Lazarevic D, Rao AP, Pires Marafon D, Ruperto N, Martini A, Ravelli A. Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care. Arthritis Care Res (Hoboken). 2017 Dec 15. doi: 10.1002/acr.23491. [Epub ahead of print] [Abstract Varnier GC, Rosina S, Ferrari C, Pistorio A, Consolaro A, Bovis F, Dalprà S, Pilkington C, Maillard S, Civino A, Tsitsami E, de Inocencio J, Jelusic M, Vojinovic J, Espada G, Makay B, Katsicas MM, Pratsidou-Gertsi P, Lazarevic D, Rao AP, Pires Marafon D, Ruperto N, Martini A, Ravelli A. Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care. Arthritis Care Res (Hoboken). 2017 Dec 15. doi: 10.1002/acr.23491. [Epub ahead of print]]
  32. Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, Oakley P, Benveniste O, Danieli MG, Danko K, Thuy NTP, Vazquez-Del Mercado M, Andersson H, De Paepe B, deBleecker JL, Maurer B, McCann LJ, Pipitone N, McHugh N, Betteridge ZE, New P, Cooper RG, Ollier WE, Lamb JA, Krogh NS, Lundberg IE, Chinoy H; all EuroMyositis contributors The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis. 2018 Jan;77(1):30-39. doi: 10.1136/annrheumdis-2017-211868. Epub 2017 Aug 30. [Abstract Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, Oakley P, Benveniste O, Danieli MG, Danko K, Thuy NTP, Vazquez-Del Mercado M, Andersson H, De Paepe B, deBleecker JL, Maurer B, McCann LJ, Pipitone N, McHugh N, Betteridge ZE, New P, Cooper RG, Ollier WE, Lamb JA, Krogh NS, Lundberg IE, Chinoy H; all EuroMyositis contributors The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis. 2018 Jan;77(1):30-39. doi: 10.1136/annrheumdis-2017-211868. Epub 2017 Aug 30.]
  33. Challa D, Crowson CS, Niewold TB, Reed AM; CARRA Legacy Registry Investigators. Predictors of changes in disease activity among children with juvenile dermatomyositis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry. Clin Rheumatol. 2017 Nov 23. doi: 10.1007/s10067-017-3901-5. [Epub ahead of print] [Abstract Challa D, Crowson CS, Niewold TB, Reed AM; CARRA Legacy Registry Investigators. Predictors of changes in disease activity among children with juvenile dermatomyositis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry. Clin Rheumatol. 2017 Nov 23. doi: 10.1007/s10067-017-3901-5. [Epub ahead of print]]
  34. Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, Lahdenne P, Magnusson B, Nistala K, Ozen S, Pilkington C, Ravelli A, Russo R, Uziel Y, van Brussel M, van der Net J, Vastert S, Wedderburn LR, Wulffraat N, McCann LJ, van Royen-Kerkhof A. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017 Feb;76(2):329-340. doi: 10.1136/annrheumdis-2016-209247. Epub 2016 Aug 11. Review. [Abstract Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, Lahdenne P, Magnusson B, Nistala K, Ozen S, Pilkington C, Ravelli A, Russo R, Uziel Y, van Brussel M, van der Net J, Vastert S, Wedderburn LR, Wulffraat N, McCann LJ, van Royen-Kerkhof A. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017 Feb;76(2):329-340. doi: 10.1136/annrheumdis-2016-209247. Epub 2016 Aug 11. Review.]
  35. Park JK, Mecoli CA, Alexanderson H, Regardt M, Christopher-Stine L, Casal-Domínguez M, de Groot I, Sarver C, Lundberg IE, Bingham CO 3rd, Song YW. Advancing the Development of Patient-reported Outcomes for Adult Myositis at OMERACT 2016: An International Delphi Study. Rheumatol. 2017 Nov;44(11):1683-1687. doi: 10.3899/jrheum.161252. Epub 2017 Aug 1. [Abstract Park JK, Mecoli CA, Alexanderson H, Regardt M, Christopher-Stine L, Casal-Domínguez M, de Groot I, Sarver C, Lundberg IE, Bingham CO 3rd, Song YW. Advancing the Development of Patient-reported Outcomes for Adult Myositis at OMERACT 2016: An International Delphi Study. Rheumatol. 2017 Nov;44(11):1683-1687. doi: 10.3899/jrheum.161252. Epub 2017 Aug 1.]
  36. Aggarwal R, Loganathan P, Koontz D, Qi Z, Reed AM, Oddis CV. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford). 2017 Feb;56(2):247-254. doi: 10.1093/rheumatology/kew396. Epub 2016 Nov 11. [Abstract Aggarwal R, Loganathan P, Koontz D, Qi Z, Reed AM, Oddis CV. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford). 2017 Feb;56(2):247-254. doi: 10.1093/rheumatology/kew396. Epub 2016 Nov 11.]
  37. Lundberg IE, Vencovsky J. International collaboration including patients is essential to develop new therapies for patients with myositis. Curr Opin Rheumatol. 2017 May;29(3):234-240. doi: 10.1097/BOR.0000000000000384. Review [Abstract Lundberg IE, Vencovsky J. International collaboration including patients is essential to develop new therapies for patients with myositis. Curr Opin Rheumatol. 2017 May;29(3):234-240. doi: 10.1097/BOR.0000000000000384. Review]
  38. Leclair V, Regardt M, Wojcik S, Hudson M; Canadian Inflammatory Myopathy Study (CIMS). Health-Related Quality of Life (HRQoL) in Idiopathic Inflammatory Myopathy: A Systematic Review. PLoS One. 2016 Aug 9;11(8):e0160753. doi: 10.1371/journal.pone.0160753. eCollection 2016. [Abstract Leclair V, Regardt M, Wojcik S, Hudson M; Canadian Inflammatory Myopathy Study (CIMS). Health-Related Quality of Life (HRQoL) in Idiopathic Inflammatory Myopathy: A Systematic Review. PLoS One. 2016 Aug 9;11(8):e0160753. doi: 10.1371/journal.pone.0160753. eCollection 2016.]
  39. Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, Fischbach M, Magnusson B, Sterba G, Avcin T, Brochard K, Corona F, Dressler F, Gerloni V, Apaz MT, Bracaglia C, Cespedes-Cruz A, Cimaz R, Couillault G, Joos R, Quartier P, Russo R, Tardieu M, Wulffraat N, Bica B, Dolezalova P, Ferriani V, Flato B, Bernard-Medina AG, Herlin T, Trachana M, Meini A, Allain-Launay E, Pilkington C, Vargova V, Wouters C, Angioloni S, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO). Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016 Feb 13;387(10019):671-8. doi: 10.1016/S0140-6736(15)01021-1. Epub 2015 Nov 30. [Abstract Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, Fischbach M, Magnusson B, Sterba G, Avcin T, Brochard K, Corona F, Dressler F, Gerloni V, Apaz MT, Bracaglia C, Cespedes-Cruz A, Cimaz R, Couillault G, Joos R, Quartier P, Russo R, Tardieu M, Wulffraat N, Bica B, Dolezalova P, Ferriani V, Flato B, Bernard-Medina AG, Herlin T, Trachana M, Meini A, Allain-Launay E, Pilkington C, Vargova V, Wouters C, Angioloni S, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO). Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016 Feb 13;387(10019):671-8. doi: 10.1016/S0140-6736(15)01021-1. Epub 2015 Nov 30.]
  40. Regardt M, Basharat P, Christopher-Stine L, Sarver C, Björn A, Lundberg IE, Wook Song Y, Bingham CO 3rd, Alexanderson H. Patients' Experience of Myositis and Further Validation of a Myositis-specific Patient Reported Outcome Measure - Establishing Core Domains and Expanding Patient Input on Clinical Assessment in Myositis. Report from OMERACT 12. J Rheumatol. 2015 Dec;42(12):2492-5. doi: 10.3899/jrheum.141243. Epub 2015 May 1. [Abstract Regardt M, Basharat P, Christopher-Stine L, Sarver C, Björn A, Lundberg IE, Wook Song Y, Bingham CO 3rd, Alexanderson H. Patients' Experience of Myositis and Further Validation of a Myositis-specific Patient Reported Outcome Measure - Establishing Core Domains and Expanding Patient Input on Clinical Assessment in Myositis. Report from OMERACT 12. J Rheumatol. 2015 Dec;42(12):2492-5. doi: 10.3899/jrheum.141243. Epub 2015 May 1.]
  41. Anyanwu CO, Fiorentino DF, Chung L, Dzuong C, Wang Y, Okawa J, Carr K, Propert KJ, Werth VP. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol. 2015 Oct;173(4):969-74. doi: 10.1111/bjd.13915. Epub 2015 Aug 11. [Abstract Anyanwu CO, Fiorentino DF, Chung L, Dzuong C, Wang Y, Okawa J, Carr K, Propert KJ, Werth VP. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol. 2015 Oct;173(4):969-74. doi: 10.1111/bjd.13915. Epub 2015 Aug 11.]
  42. Reed AM, Crowson CS, Hein M, de Padilla CL, Olazagasti JM, Aggarwal R, Ascherman DP, Levesque MC, Oddis CV; RIM Study Group. Biologic predictors of clinical improvement in rituximab-treated refractory myositis. BMC Musculoskelet Disord. 2015 Sep 17;16:257. doi: 10.1186/s12891-015-0710-3. PMID: 26382217. [Abstract Reed AM, Crowson CS, Hein M, de Padilla CL, Olazagasti JM, Aggarwal R, Ascherman DP, Levesque MC, Oddis CV; RIM Study Group. Biologic predictors of clinical improvement in rituximab-treated refractory myositis. BMC Musculoskelet Disord. 2015 Sep 17;16:257. doi: 10.1186/s12891-015-0710-3. PMID: 26382217.]
  43. Almeida B, Campanilho-Marques R, Arnold K, Pilkington CA, Wedderburn LR, Nistala K; Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Analysis of published criteria for Clinically Inactive Disease in a large Juvenile Dermatomyositis cohort shows that skin disease is underestimated. Arthritis Rheum, 2015 Sep;67(9):2495-502. doi: 10.1002/art.39200. [Epub ahead of print] [Abstract Almeida B, Campanilho-Marques R, Arnold K, Pilkington CA, Wedderburn LR, Nistala K; Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Analysis of published criteria for Clinically Inactive Disease in a large Juvenile Dermatomyositis cohort shows that skin disease is underestimated. Arthritis Rheum, 2015 Sep;67(9):2495-502. doi: 10.1002/art.39200. [Epub ahead of print]]
  44. Sanner H, Sjaastad I, Flatø B. Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. Rheumatology (Oxford), 2014 Sep 53(9):1578-85. Epub 2014 Sep 1. [Pub Med Sanner H, Sjaastad I, Flatø B. Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. Rheumatology (Oxford), 2014 Sep 53(9):1578-85. Epub 2014 Sep 1.]
  45. Lloyd TE, Mammen AL, Amato AA, Weiss MD, Needham M, Greenberg SA. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology, 2014 Jul 83(5):426-33. Epub 2014 Jul 29. [Pub Med Lloyd TE, Mammen AL, Amato AA, Weiss MD, Needham M, Greenberg SA. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology, 2014 Jul 83(5):426-33. Epub 2014 Jul 29.]
  46. McCann LJ, Arnold K, Pilkington CA, Huber AM, Ravelli A, Beard L, Beresford MW, Wedderburn LR. Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research. Pediatr Rheumatol Online J, 2014 Jul 12:31. Epub 2014 Jul 21. [Pub Med McCann LJ, Arnold K, Pilkington CA, Huber AM, Ravelli A, Beard L, Beresford MW, Wedderburn LR. Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research. Pediatr Rheumatol Online J, 2014 Jul 12:31. Epub 2014 Jul 21.]
  47. Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castelino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR; CTD-ILD Special Interest Group. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax, 2014 May 69(5):428-36.. Epub 2014 May 1. [Pub Med Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castelino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR; CTD-ILD Special Interest Group. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax, 2014 May 69(5):428-36.. Epub 2014 May 1.]
  48. Alexanderson H, Del Grande M, Bingham CO 3rd, Orbai AM, Sarver C, Clegg-Smith K, Lundberg IE, Song YW, Christopher-Stine L. Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 Myositis Special Interest Group. J Rheumatol. 2014 Mar;41(3):581-92. doi: 10.3899/jrheum.131247. Epub 2014 Jan 15. Review. [Abstract Alexanderson H, Del Grande M, Bingham CO 3rd, Orbai AM, Sarver C, Clegg-Smith K, Lundberg IE, Song YW, Christopher-Stine L. Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 Myositis Special Interest Group. J Rheumatol. 2014 Mar;41(3):581-92. doi: 10.3899/jrheum.131247. Epub 2014 Jan 15. Review.]
  49. Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love MO, Levesque MC; RIM Study Group, Oddis CV. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol, 2014 Mar 66(3):740-9. Epub 2014 Mar 1. [Pub Med Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love MO, Levesque MC; RIM Study Group, Oddis CV. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol, 2014 Mar 66(3):740-9. Epub 2014 Mar 1.]
  50. Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, Wulffraat NM, Malattia C, Garay SM, Hofer M, Quartier P, Dolezalova P, Penades IC, Ferriani VP, Ganser G, Kasapcopur O, Melo-Gomes JA, Reed AM, Wierzbowska M, Rider LG, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO). The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann rheum Dis, 2013 May 72(5):686-93. doi: 10.1136/annrheumdis-2012-201483. Epub 2013 May. [Pub Med Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, Wulffraat NM, Malattia C, Garay SM, Hofer M, Quartier P, Dolezalova P, Penades IC, Ferriani VP, Ganser G, Kasapcopur O, Melo-Gomes JA, Reed AM, Wierzbowska M, Rider LG, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO). The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann rheum Dis, 2013 May 72(5):686-93. doi: 10.1136/annrheumdis-2012-201483. Epub 2013 May.]
  51. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE; RIM Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum, 2013 Feb 65(2):314-24. Epub 2013 Feb 1. [Pub Med Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE; RIM Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum, 2013 Feb 65(2):314-24. Epub 2013 Feb 1.]
  52. Alexanderson H, Reed AM, Ytterberg SR. The Myositis Activities Profile -- initial validation for assessment of polymyositis/dermatomyositis in the USA. J. Rheumatol, 2012 Nov 39(11):2134-41. doi: 10.3899/jrheum.120504. Epub 2012 Sep 1. [Pub Med Alexanderson H, Reed AM, Ytterberg SR. The Myositis Activities Profile -- initial validation for assessment of polymyositis/dermatomyositis in the USA. J. Rheumatol, 2012 Nov 39(11):2134-41. doi: 10.3899/jrheum.120504. Epub 2012 Sep 1.]
  53. Goreshi R, Okawa J, Rose M, Feng R, Lee LA, Hansen CB, Bangert CA, Connolly MK, Davis MD, Callen JP, Fett NM, Fakharzadeh SS, Clarke JT, Werth VP. Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM. J Invest Dertmatol. 2012 Apr 132(4):1117-24. Epub 2012 Apr 1. [Pub Med Goreshi R, Okawa J, Rose M, Feng R, Lee LA, Hansen CB, Bangert CA, Connolly MK, Davis MD, Callen JP, Fett NM, Fakharzadeh SS, Clarke JT, Werth VP. Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM. J Invest Dertmatol. 2012 Apr 132(4):1117-24. Epub 2012 Apr 1.]
  54. Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, Wulffraat NM, Malattia C, Garay SM, Hofer M, Quartier P, Dolezalova P, Penades IC, Ferriani VP, Ganser G, Kasapcopur O, Melo-Gomes JA, Reed AM, Wierzbowska M, Rider LG, Martini A, Ruperto N; for the Paediatric Rheumatology International Trials Organisation (PRINTO). The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis, Ann Rheum Dis, 2012 Jun 26 [Epub ahead of print]. [Abstract Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, Wulffraat NM, Malattia C, Garay SM, Hofer M, Quartier P, Dolezalova P, Penades IC, Ferriani VP, Ganser G, Kasapcopur O, Melo-Gomes JA, Reed AM, Wierzbowska M, Rider LG, Martini A, Ruperto N; for the Paediatric Rheumatology International Trials Organisation (PRINTO). The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis, Ann Rheum Dis, 2012 Jun 26 [Epub ahead of print].]
  55. Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, Curran M, Feldman BM, Gewanter H, Griffin T, Haines K, Hoeltzel MF, Isgro J, Kahn P, Lang B, Lawler P, Shaham B, Schmeling H, Scuccimarri R, Shishov M, Stringer E, Wohrley J, Ilowite NT, Wallace C; Juvenile Dermatomyositis Subcommittee of the Childhood Arthritis and Rheumatology Research Alliance, Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference, Arthritis Care Res (Hoboken), 2012 Apr 64(4):546-53. doi 10.1002/acr.20695. [Abstract Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, Curran M, Feldman BM, Gewanter H, Griffin T, Haines K, Hoeltzel MF, Isgro J, Kahn P, Lang B, Lawler P, Shaham B, Schmeling H, Scuccimarri R, Shishov M, Stringer E, Wohrley J, Ilowite NT, Wallace C; Juvenile Dermatomyositis Subcommittee of the Childhood Arthritis and Rheumatology Research Alliance, Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference, Arthritis Care Res (Hoboken), 2012 Apr 64(4):546-53. doi 10.1002/acr.20695.]
  56. Goreshi R, Chock M, Foering K, Feng R, Okawa J, Rose M, Fiorentino D, Werth V. Quality of life in dermatomyositis. J Am Acad Dermatol. 2011 Dec;65(6):1107-16. [PubMed Goreshi R, Chock M, Foering K, Feng R, Okawa J, Rose M, Fiorentino D, Werth V. Quality of life in dermatomyositis. J Am Acad Dermatol. 2011 Dec;65(6):1107-16.] 
  57. Sanner H, Kirkhus E, Merckoll E, Tollisen A, Røisland M, Lie BA, Taraldsrud E, Gran JT, Flatø B. Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: A case-control study, Arthritis Care Res (Hoboken), 2010 Aug 62(8):1103-11.PMID: 20506141. [Pub Med Sanner H, Kirkhus E, Merckoll E, Tollisen A, Røisland M, Lie BA, Taraldsrud E, Gran JT, Flatø B. Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: A case-control study, Arthritis Care Res (Hoboken), 2010 Aug 62(8):1103-11.PMID: 20506141.]  
  58. Ruperto N, Pistorio A, Ravelli A, Rider LG, Pilkington C, Oliveira S, Wulffraat N, Espada G, Garay S, Cuttica R, Hofer M, Quartier P, Melo-Gomes J, Reed AM, Wierzbowska M, Feldman BM, Harjacek M, Huppertz HI, Nielsen S, Flatø B, Lahdenne P, Michels H, Murray KJ, Punaro L, Rennebohm R, Russo R, Balogh Z, Rooney M, Pachman LM, Wallace C, Hashkes P, Lovell DJ, Giannini EH, Martini A; for Pædiatric Rheumatology International Trials Organisation (PRINTO) the Pediatric Rheumatology Collaborative Study Group (PRCSG). The pediatric rheumatology international trials organization provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis, Arthritis Care Res (Hoboken), 2010 Nov 62(11):1533-41. doi: 10.1002/acr.20280. Epub 2010 Jun 25. [Pub Med Ruperto N, Pistorio A, Ravelli A, Rider LG, Pilkington C, Oliveira S, Wulffraat N, Espada G, Garay S, Cuttica R, Hofer M, Quartier P, Melo-Gomes J, Reed AM, Wierzbowska M, Feldman BM, Harjacek M, Huppertz HI, Nielsen S, Flatø B, Lahdenne P, Michels H, Murray KJ, Punaro L, Rennebohm R, Russo R, Balogh Z, Rooney M, Pachman LM, Wallace C, Hashkes P, Lovell DJ, Giannini EH, Martini A; for Pædiatric Rheumatology International Trials Organisation (PRINTO) the Pediatric Rheumatology Collaborative Study Group (PRCSG). The pediatric rheumatology international trials organization provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis, Arthritis Care Res (Hoboken), 2010 Nov 62(11):1533-41. doi: 10.1002/acr.20280. Epub 2010 Jun 25.]
  59. Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, Feldman BM, Wright SJ, Lindsley CB, Pachman LM, Villalba ML, Lovell DJ, Bowyer SL, Plotz PH, Miller FW, Hicks JE. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies, Arthritis Care Res (Hoboken), 2010 Apr 62(4):465-72. [Pub Med Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, Feldman BM, Wright SJ, Lindsley CB, Pachman LM, Villalba ML, Lovell DJ, Bowyer SL, Plotz PH, Miller FW, Hicks JE. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies, Arthritis Care Res (Hoboken), 2010 Apr 62(4):465-72.]
  60. Hilton-Jones D, Miller A, Parton M, Holton J, Sewry C, Hanna MG. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008, Neuromuscul Disord, 2010 Feb 20(2):142-7. Epub 2010 Jan 13. [Abstract Hilton-Jones D, Miller A, Parton M, Holton J, Sewry C, Hanna MG. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008, Neuromuscul Disord, 2010 Feb 20(2):142-7. Epub 2010 Jan 13.]
  61. Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, Pachman LM, Pilkington C, Reed AM, Rennebohm RM, Rider LG, Wallace CA, Feldman BM. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference, Arthritis Care Res (Hoboken), 2010 Feb 62(2):219-25.PMID: 20191521. [Pub Med Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, Pachman LM, Pilkington C, Reed AM, Rennebohm RM, Rider LG, Wallace CA, Feldman BM. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference, Arthritis Care Res (Hoboken), 2010 Feb 62(2):219-25.PMID: 20191521.]
  62. Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, Maillard S, Oliveira SK, Sztajnbok F, Cuttica R, Beltramelli M, Corona F, Katsicas MM, Russo R, Ferriani V, Burgos-Vargas R, Magni-Manzoni S, Solis-Valleoj E, Bandeira M, Zulian F, Baca V, Cortis E, Falcini F, Alessio M, Alpigiani MG, Gerloni V, Saad-Magalhaes C, Podda R, Silva CA, Lepore L, Felici E, Rossi F, Sala E, Martini A. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken), 2010 Jan 15 62(1):63-72.PMID: 20191492. [Pub Med Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, Maillard S, Oliveira SK, Sztajnbok F, Cuttica R, Beltramelli M, Corona F, Katsicas MM, Russo R, Ferriani V, Burgos-Vargas R, Magni-Manzoni S, Solis-Valleoj E, Bandeira M, Zulian F, Baca V, Cortis E, Falcini F, Alessio M, Alpigiani MG, Gerloni V, Saad-Magalhaes C, Podda R, Silva CA, Lepore L, Felici E, Rossi F, Sala E, Martini A. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken), 2010 Jan 15 62(1):63-72.PMID: 20191492.]
  63. Sanner H, Gran JT, Sjaastad I, Flat B; Division Rikshospitalet, Medical Faculty, University of Oslo Oslo University Hospital, Rikshospitalet, Oslo, Norway. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset, Rheumatology (Oxford), 2009 Dec 48(12):1541-7. [Pub Med Sanner H, Gran JT, Sjaastad I, Flat B; Division Rikshospitalet, Medical Faculty, University of Oslo Oslo University Hospital, Rikshospitalet, Oslo, Norway. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset, Rheumatology (Oxford), 2009 Dec 48(12):1541-7.]
  64. Harris-Love MO, Shrader JA, Koziol D, Pahlajani N, Jain M, Smith M, Cintas HL, McGarvey CL, James-Newton L, Pokrovnichka A, Moini B, Cabalar I, Lovell DJ, Wesley R, Plotz PH, Miller FW, Hicks JE, Rider LG. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis, Rheumatology (Oxford), 2009 Feb 48(2):134-9. Epub 2008 Dec 11. [Pub Med Harris-Love MO, Shrader JA, Koziol D, Pahlajani N, Jain M, Smith M, Cintas HL, McGarvey CL, James-Newton L, Pokrovnichka A, Moini B, Cabalar I, Lovell DJ, Wesley R, Plotz PH, Miller FW, Hicks JE, Rider LG. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis, Rheumatology (Oxford), 2009 Feb 48(2):134-9. Epub 2008 Dec 11.]
  65. Klein RQ, Bangert CA, Costner M, Connolly MK, Tanikawa A, Okawa J, Rose M, Fakharzadeh SS, Fiorentino D, Lee LA, Sontheimer RD, Taylor L, Troxel AB, Werth VP. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis, Br J Dermatol, 2008 Sep 159(4):887-94. Epub 2008 Jul 4. [Pub Med Klein RQ, Bangert CA, Costner M, Connolly MK, Tanikawa A, Okawa J, Rose M, Fakharzadeh SS, Fiorentino D, Lee LA, Sontheimer RD, Taylor L, Troxel AB, Werth VP. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis, Br J Dermatol, 2008 Sep 159(4):887-94. Epub 2008 Jul 4.]
  66. Huber AM, Lachenbruch PA, Dugan EM, Miller FW, Rider LG; Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats, Arthritis Rheum, 2008 Mar 15 59(3):352-6. [Pub Med Huber AM, Lachenbruch PA, Dugan EM, Miller FW, Rider LG; Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats, Arthritis Rheum, 2008 Mar 15 59(3):352-6.]
  67. Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, Lindsley CB, Rennebohm RM, Wallace CA, Passo MH, Reed AM, Bowyer SL, Ballinger SH, Miller FW, Rider LG; Juvenile Dermatomyositis Disease Activity Collaborative Study Group Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. Arthritis Rheum. 2008 Feb 15;59(2):214-21. [Pub Med Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, Lindsley CB, Rennebohm RM, Wallace CA, Passo MH, Reed AM, Bowyer SL, Ballinger SH, Miller FW, Rider LG; Juvenile Dermatomyositis Disease Activity Collaborative Study Group Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. Arthritis Rheum. 2008 Feb 15;59(2):214-21.]
  68. Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G, Brunner J, Dannecker G, Silva CA, Stanevicha V, Cate RT, van Suijlekom-Smit LW, Voygioyka O, Fischbach M, Foeldvari I, Hilario O, Modesto C, Saurenmann RK, Sauvain MJ, Scheibel I, Sommelet D, Tambic-Bukovac L, Barcellona R, Brik R, Ehl S, Jovanovic M, Rovensky J, Bagnasco F, Lovell DJ, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study, Arthritis Rheum, 2008 Jan 15 59(1):4-13. [Pub Med Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G, Brunner J, Dannecker G, Silva CA, Stanevicha V, Cate RT, van Suijlekom-Smit LW, Voygioyka O, Fischbach M, Foeldvari I, Hilario O, Modesto C, Saurenmann RK, Sauvain MJ, Scheibel I, Sommelet D, Tambic-Bukovac L, Barcellona R, Brik R, Ehl S, Jovanovic M, Rovensky J, Bagnasco F, Lovell DJ, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study, Arthritis Rheum, 2008 Jan 15 59(1):4-13.]
  69. Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, Lindsley CB, Rennebohm RM, Wallace CA, Passo MH, Reed AM, Bowyer SL, Ballinger SH, Miller FW, Rider LG; in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group, The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy, Rheumatology (Oxford), 2007 Oct 46(10):1606-11. [Pub Med Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, Lindsley CB, Rennebohm RM, Wallace CA, Passo MH, Reed AM, Bowyer SL, Ballinger SH, Miller FW, Rider LG; in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group, The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy, Rheumatology (Oxford), 2007 Oct 46(10):1606-11.]
  70. Wedderburn LR, Varsani H, Li CK, Newton KR, Amato AA, Banwell B, Bove KE, Corse AM, Emslie-Smith A, Harding B, Hoogendijk J, Lundberg IE, Marie S, Minetti C, Nennesmo I, Rushing EJ, Sewry C, Charman SC, Pilkington CA, Holton JL. UK Juvenile Dermatomyositis Research Group. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials, Arthritis Rheum, 2007 Oct 15 57(7):1192-201. [Pub Med Wedderburn LR, Varsani H, Li CK, Newton KR, Amato AA, Banwell B, Bove KE, Corse AM, Emslie-Smith A, Harding B, Hoogendijk J, Lundberg IE, Marie S, Minetti C, Nennesmo I, Rushing EJ, Sewry C, Charman SC, Pilkington CA, Holton JL. UK Juvenile Dermatomyositis Research Group. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials, Arthritis Rheum, 2007 Oct 15 57(7):1192-201.]
  71. Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, Domsic R, Ascherman DP. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy, Arthritis Rheum, 2007 Sep 56(9):3125-31. [Pub Med Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, Domsic R, Ascherman DP. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy, Arthritis Rheum, 2007 Sep 56(9):3125-31.]
  72. Alexanderson H, Broman L, Tollback A, Josefson A, Lundberg IE, Stenstrom CH, Functional index-2: Validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis, Arthritis Rheum, 2006 Feb 15 55(1):114-22. [Pub Med Alexanderson H, Broman L, Tollback A, Josefson A, Lundberg IE, Stenstrom CH, Functional index-2: Validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis, Arthritis Rheum, 2006 Feb 15 55(1):114-22.]
  73. Chung YL, Rider LG, Bell JD, Summers RM, Zemel LS, Rennebohm RM, Passo MH, Hicks J, Miller FW, Scott DL; Juvenile Dermatomyositis Disease Activity Collaborative Study Group, Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies, Arthritis Rheum, 2005 Aug 15 53(4):565-70. [Pub Med Chung YL, Rider LG, Bell JD, Summers RM, Zemel LS, Rennebohm RM, Passo MH, Hicks J, Miller FW, Scott DL; Juvenile Dermatomyositis Disease Activity Collaborative Study Group, Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies, Arthritis Rheum, 2005 Aug 15 53(4):565-70.]
  74. Ponyi A, Borgulya G, Constantin T, Vancsa A, Gergely L, Danko K. Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology (Oxford), 2005 Jan 44(1):83-8. Epub 2004 Sep 20. [Pub Med Ponyi A, Borgulya G, Constantin T, Vancsa A, Gergely L, Danko K. Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology (Oxford), 2005 Jan 44(1):83-8. Epub 2004 Sep 20.]
  75. Smith RL, Sundberg J, Shamiyah E, Dyer A, Pachman LM. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops, J Rheumatol, 2004 Aug 31(8):1644-9. [Pub Med Smith RL, Sundberg J, Shamiyah E, Dyer A, Pachman LM. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops, J Rheumatol, 2004 Aug 31(8):1644-9.]
  76. Miller FW, Rider LG, Plotz PH, Rutkove SB, Pestronk A, Wortmann RL, Lundberg IE, Argov Z, Isenberg DA, Lacomis D, Oddis CV, Polymyositis: an overdiagnosed entity, Neurology, 2004 Jul 27 63(2):402. [Pub Med Miller FW, Rider LG, Plotz PH, Rutkove SB, Pestronk A, Wortmann RL, Lundberg IE, Argov Z, Isenberg DA, Lacomis D, Oddis CV, Polymyositis: an overdiagnosed entity, Neurology, 2004 Jul 27 63(2):402.]
  77. Rennebohm RM, Jones K, Huber AM, Ballinger SH, Bowyer SL, Feldman BM, Hicks J, Katona IM, Lindsley CB, Miller FW, Passo MH, Perez MD, Reed AM, Wallace CA, White PH, Zemel LS, Lachenbruch PA, Hayes JR, Rider LG; Juvenile Dermatomyositis Disease Activity Collaborative Study Group, Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale, Arthritis Rheum, 2004 Jun 15 51(3):365-70. [Pub Med Rennebohm RM, Jones K, Huber AM, Ballinger SH, Bowyer SL, Feldman BM, Hicks J, Katona IM, Lindsley CB, Miller FW, Passo MH, Perez MD, Reed AM, Wallace CA, White PH, Zemel LS, Lachenbruch PA, Hayes JR, Rider LG; Juvenile Dermatomyositis Disease Activity Collaborative Study Group, Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale, Arthritis Rheum, 2004 Jun 15 51(3):365-70.]
  78. Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, Zemel LS, Wallace CA, Ballinger SH, Passo MH, Reed AM, Summers RM, White PH, Katona IM, Miller FW, Lachenbruch PA, Rider LG, Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies, Arthritis Rheum, 2004 May 50(5):1595-603. [Pub Med Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, Zemel LS, Wallace CA, Ballinger SH, Passo MH, Reed AM, Summers RM, White PH, Katona IM, Miller FW, Lachenbruch PA, Rider LG, Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies, Arthritis Rheum, 2004 May 50(5):1595-603.]
  79. Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM, Garay S, Kuis W, Machado C, Pachman L, Prieur AM, Rider LG, Silverman E, Tsitsami E, Woo P, Giannini EH, Martini A; Paediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG), Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis, Rheumatology (Oxford), 2003 Dec 42(12):1452-9. Epub 2003 Jun 27. [Pub Med Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM, Garay S, Kuis W, Machado C, Pachman L, Prieur AM, Rider LG, Silverman E, Tsitsami E, Woo P, Giannini EH, Martini A; Paediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG), Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis, Rheumatology (Oxford), 2003 Dec 42(12):1452-9. Epub 2003 Jun 27.]
  80. Miller FW, Rider LG, Plotz PH, Isenberg DA, Oddis CV, Diagnostic criteria for polymyositis and dermatomyositis, Lancet, 2003 Nov 22 362(9397):1762-3; author reply 1763. [Pub Med Miller FW, Rider LG, Plotz PH, Isenberg DA, Oddis CV, Diagnostic criteria for polymyositis and dermatomyositis, Lancet, 2003 Nov 22 362(9397):1762-3; author reply 1763.]
  81. Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence, Arthritis Rheum, 2003 Feb 15 49(1):7-15. [Pub Med Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence, Arthritis Rheum, 2003 Feb 15 49(1):7-15.]
  82. Sultan SM, Ioannou Y, Moss K, Isenberg DA, Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality, Rheumatology (Oxford), 2002 Jan 41(1):22-6. [Pub Med Sultan SM, Ioannou Y, Moss K, Isenberg DA, Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality, Rheumatology (Oxford), 2002 Jan 41(1):22-6.]
  83. Rider LG*, AS Schiffenbauer*, M Zito, KL Lim, A Ahmed, LS Zemel, RM Rennebohm, MH Passo, RM Summers, JE Hicks, PA Lachenbruch, MP Heyes, FW Miller, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group; Juvenile Dermatomyositis Disease Activity Collaborative Study Group, Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies, Clin. Chem., 2002 Oct 48(10):1681-8; * These authors contributed equally. [Pub Med Rider LG*, AS Schiffenbauer*, M Zito, KL Lim, A Ahmed, LS Zemel, RM Rennebohm, MH Passo, RM Summers, JE Hicks, PA Lachenbruch, MP Heyes, FW Miller, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group; Juvenile Dermatomyositis Disease Activity Collaborative Study Group, Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies, Clin. Chem., 2002 Oct 48(10):1681-8; * These authors contributed equally.]
  84. Huber A, J.E. Hicks, P.A. Lachenbruch, M.D. Perez, L.S. Zemel, R.M. Rennebohm, C.A. Wallace, C.B. Lindsley, M.H. Passo, S.H. Ballinger, S.L. Bowyer, A.M., P.H. White, I.M. Katona, F.W. Miller, L.G. Rider*, and B.M. Feldman*; Juvenile Dermatomyositis Disease Activity Collaborative Study Group, Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. III. The Childhood Health Assessment Questionnaire (CHAQ), J Rheumatol, 2001 May 28(5):1106-11; * These authors contributed equally. [Pub Med Huber A, J.E. Hicks, P.A. Lachenbruch, M.D. Perez, L.S. Zemel, R.M. Rennebohm, C.A. Wallace, C.B. Lindsley, M.H. Passo, S.H. Ballinger, S.L. Bowyer, A.M., P.H. White, I.M. Katona, F.W. Miller, L.G. Rider*, and B.M. Feldman*; Juvenile Dermatomyositis Disease Activity Collaborative Study Group, Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. III. The Childhood Health Assessment Questionnaire (CHAQ), J Rheumatol, 2001 May 28(5):1106-11; * These authors contributed equally.]
  85. Lovell D.J., CB. Lindsley, RM. Rennebohm, SH. Ballinger, SL. Bowyer, EH Giannini, JE Hicks, JE Levinson, R. Mier, LM Pachman, MH Passo, MD Perez, AM Reed, KN Schickler, M. Smith, LS Zemel, LG Rider, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group, Development of validated disease activity and disease damage indices for the juvenile idiopathic inflammatory myopathies: II. The Childhood Myositis Assessment Scale: A quantitative tool for the evaluation of muscle function, Arthritis Rheum, 1999 Oct 42(10):2213-9. [Pub Med Lovell D.J., CB. Lindsley, RM. Rennebohm, SH. Ballinger, SL. Bowyer, EH Giannini, JE Hicks, JE Levinson, R. Mier, LM Pachman, MH Passo, MD Perez, AM Reed, KN Schickler, M. Smith, LS Zemel, LG Rider, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group, Development of validated disease activity and disease damage indices for the juvenile idiopathic inflammatory myopathies: II. The Childhood Myositis Assessment Scale: A quantitative tool for the evaluation of muscle function, Arthritis Rheum, 1999 Oct 42(10):2213-9.]
  86. Rider, L.G., B.M. Feldman, M.D. Perez, R.M. Rennebohm, C.B. Lindsley, L.S. Zemel, C.A. Wallace, S.H. Ballinger, S.L. Bowyer, A.M. Reed, M.H. Passo, I.M. Katona, F.W. Miller, and P.A. Lachenbruch; Juvenile Dermatomyositis Disease Activity Collaborative Study Group, Development of Validated Disease Activity and Disease Damage Indices for the Juvenile Idiopathic Inflammatory Myopathies: I. Physician and Parent/Patient Global Assessments, Arthritis Rheum, 1997 Nov 40(11):1976-83. [Pub Med Rider, L.G., B.M. Feldman, M.D. Perez, R.M. Rennebohm, C.B. Lindsley, L.S. Zemel, C.A. Wallace, S.H. Ballinger, S.L. Bowyer, A.M. Reed, M.H. Passo, I.M. Katona, F.W. Miller, and P.A. Lachenbruch; Juvenile Dermatomyositis Disease Activity Collaborative Study Group, Development of Validated Disease Activity and Disease Damage Indices for the Juvenile Idiopathic Inflammatory Myopathies: I. Physician and Parent/Patient Global Assessments, Arthritis Rheum, 1997 Nov 40(11):1976-83.]